Dr. Matthew A. Kutny
Claim this profileChildren's Hospital of Alabama
Expert in Leukemia
Studies Lymphoblastic Leukemia-Lymphoma
36 reported clinical trials
82 drugs studied
Area of expertise
1Leukemia
Global LeaderPhiladelphia chromosome positive
BCR-ABL1 fusion positive
ABL-class fusion positive
2Lymphoblastic Leukemia-Lymphoma
Philadelphia chromosome positive
BCR-ABL1 fusion positive
ABL-class fusion positive
Affiliated Hospitals
Clinical Trials Matthew A. Kutny is currently running
Selumetinib vs. Chemotherapy
for Brain Cancer
This trial is comparing a new drug, selumetinib, with standard chemotherapy to treat patients with a specific type of brain tumor. The patients do not have a certain genetic mutation and are not affected by a genetic disorder. Selumetinib works by blocking enzymes needed for tumor growth, while the standard drugs kill or stop tumor cells from dividing.
Recruiting2 awards Phase 3
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
More about Matthew A. Kutny
Clinical Trial Related4 years of experience running clinical trials · Led 36 trials as a Principal Investigator · 15 Active Clinical TrialsTreatments Matthew A. Kutny has experience with
- Cyclophosphamide
- Radiation Therapy
- Mercaptopurine
- Methotrexate
- Etoposide
- Vincristine Sulfate
Breakdown of trials Matthew A. Kutny has run
Leukemia
Lymphoblastic Leukemia-Lymphoma
Acute Lymphoblastic Leukemia
Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Matthew A. Kutny specialize in?
Matthew A. Kutny focuses on Leukemia and Lymphoblastic Leukemia-Lymphoma. In particular, much of their work with Leukemia has involved Philadelphia chromosome positive patients, or patients who are BCR-ABL1 fusion positive.
Is Matthew A. Kutny currently recruiting for clinical trials?
Yes, Matthew A. Kutny is currently recruiting for 12 clinical trials in Birmingham Alabama. If you're interested in participating, you should apply.
Are there any treatments that Matthew A. Kutny has studied deeply?
Yes, Matthew A. Kutny has studied treatments such as Cyclophosphamide, Radiation Therapy, Mercaptopurine.
What is the best way to schedule an appointment with Matthew A. Kutny?
Apply for one of the trials that Matthew A. Kutny is conducting.
What is the office address of Matthew A. Kutny?
The office of Matthew A. Kutny is located at: Children's Hospital of Alabama, Birmingham, Alabama 35233 United States. This is the address for their practice at the Children's Hospital of Alabama.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.